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   MATERIALS AND METHODS 
 
 Slimming MF (prescribed to overweight women, as hard gelatine capsules, once or twice daily) were analyzed in terms of 
labelled drug/bioactive composition and dosage, therapeutic indication/claim, recommended daily dose (RDD), side 
effects/interactions and contraindications. Written consent for data use was obtained from patients.  
Table 1. MF labels composition and dose (mg); roman superscripts identify the substance in the text. *RDD not well established 
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   INTRODUCTION 
 Magistral formulas (MF) are prepared by the pharmacist for a given patient according to a prescription 
and following technical and scientific compounding standards. MF are often used in weight loss 
regimens and contain blends of drugs (D) and plant (P) extracts. Associations potentiate interactions 
and related adverse effects, compromising effectiveness and risking the patient´s health (1,2).  
 The purpose of this work was to give an overview of MF intended for slimming, prescribed by doctors, 
in a perspective of efficacy and safety. 
   RESULTS 
 
MF did not contain unlawful ingredients (3); these were used mostly in sub therapeutic doses (Table 1).  
Weight loss is a result of (a) side effect of D-III/IV (off-label use), (b) water loss due to therapeutic action (D-I/IX and  
P-V/VII/VIII), or (c) claimed appetite reduction (P-VI/X/XI).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Active ingredient (AI) 
Main therapeutic 
indication / claim 
MF1 MF2 MF3 MF4 MF5 MF6 MF7 
Usual posology in major 
pathology 
Furosemide I Diuretic 20 25 18 18 30 20-80/120 mg/day 
Chlordiazepoxide II Anxiolytic 8 8 8 8 10 30 mg (3 times/day) 
Bupropion III Antidepressant 120 100 140 150 130 150 mg (2 times/day) 
Metformine IV Antidiabetic  280 250 300 300 260 500 mg (2/3 times/day) 
Artichoke V Laxative 110 400 500 mg/day * 
Bitter orange (Citrus aurantium) VI Appetite reducer 150 200 200 200 200 50-100 mg/day * 
Centella asiatica L. VII Anti-cellulite, venotonic 400 400 750 60-120 mg/day * 
Cascara Sagrada (R. purshiana) VIII Laxative 100 130 120 150-325 mg/day * 
Phenolphthalein IX Laxative 65 100 90 85 30-200 mg/day 
Glucomannan (A. konjac) X Appetite reducer 500 1000-13000 mg/day * 
Slimalluma (Caralluma fimbriata) XI Appetite reducer 300 250 500 mg (2 times/day) * 
Table 1. MF labels composition and dose (mg); roman superscripts identify the substance in the text. *RDD not well established 
   DISCUSSION AND CONCLUSIONS 
 
Off-label uses of drugs and efficacy of sub therapeutic doses are questionable.  
D-II and D-III present risk of abuse and dependence. Combination of laxatives (MF 1,2 and 6) is not recommended, 
increasing the chances of electrolyte imbalance and dehydration, and reducing absorption of ansa diuretics.  
Clinical data to support the claims and posology of botanicals is scarce and contradictory; moreover, potential side 
effects/interactions are at times unknown and adulteration/contamination is a risk.  
Of note is the potential for interaction of P-V (inhibiting several isoenzymes of CYP450) and the association of D-I/P-V 
may cause hypovolemia and hypocaliemia.  
Even if no additional interactions were found between molecules, combinations may increase the risk of adverse 
events. Severe/fatal interactions may occur with other drugs (e.g. D-II + opioids; D-III + MAO inhibitors), so knowledge 
of patient's clinical history and related medication is of the utmost importance, when prescribing and counselling. 
Evaluation of safety and efficacy of MF is a shared responsibility of doctor and pharmacist and requires robust scientific 
data, especially regarding botanicals. 
Slimming medication alone, without lifestyle changes, is not effective in the long term and may be risky. 
